Skip to contentV
Viridian Therapeutics, Inc.
V
VRDNViridian Therapeutics, Inc. Q4 2019 · 10-K
Revenue$880.00K$880.00K+84.9% vs Q4 2018 Net Income-$10.12M-$10.12MN/M vs Q4 2018 EPS Diluted-$0.31-$0.31N/M vs Q4 2018 Operating Incomederived-$10,071,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
Operating Cash Flowderived-$7,806,000N/M Free Cash Flowderived-$7,806,000N/M Margins · derivedOperating margin-1144.4%+1051.6 pt vs Q4 2018
Net margin-1149.8%+1017.7 pt vs Q4 2018
ended Dec 31, 2019 · filed Mar 13, 2020 · 73 d after period end